CN108516974A - 用于治疗hiv的酰胺化合物 - Google Patents

用于治疗hiv的酰胺化合物 Download PDF

Info

Publication number
CN108516974A
CN108516974A CN201810393664.7A CN201810393664A CN108516974A CN 108516974 A CN108516974 A CN 108516974A CN 201810393664 A CN201810393664 A CN 201810393664A CN 108516974 A CN108516974 A CN 108516974A
Authority
CN
China
Prior art keywords
alkyl
heteroaryl
membered
independently
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810393664.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·布里吉斯
E·加纳雷斯
周建宏
M·格劳普
Y·E·胡
J·O·林克
柳琪
陆亚凡
R·D·赛图
S·D·施罗德
J·R·索默泽
W·C·特斯
J·R·张
S·E·拉泽维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108516974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN108516974A publication Critical patent/CN108516974A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201810393664.7A 2013-03-01 2014-02-28 用于治疗hiv的酰胺化合物 Pending CN108516974A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361771655P 2013-03-01 2013-03-01
US61/771,655 2013-03-01
US201361857636P 2013-07-23 2013-07-23
US61/857,636 2013-07-23
CN201480020587.0A CN105705500B (zh) 2013-03-01 2014-02-28 用于治疗hiv的酰胺化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480020587.0A Division CN105705500B (zh) 2013-03-01 2014-02-28 用于治疗hiv的酰胺化合物

Publications (1)

Publication Number Publication Date
CN108516974A true CN108516974A (zh) 2018-09-11

Family

ID=50382584

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480020587.0A Active CN105705500B (zh) 2013-03-01 2014-02-28 用于治疗hiv的酰胺化合物
CN201810393664.7A Pending CN108516974A (zh) 2013-03-01 2014-02-28 用于治疗hiv的酰胺化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480020587.0A Active CN105705500B (zh) 2013-03-01 2014-02-28 用于治疗hiv的酰胺化合物

Country Status (38)

Country Link
US (4) US9951043B2 (enExample)
EP (3) EP2961742B1 (enExample)
JP (6) JP6519486B2 (enExample)
KR (1) KR102229989B1 (enExample)
CN (2) CN105705500B (enExample)
AP (1) AP2015008717A0 (enExample)
AU (3) AU2014223973B2 (enExample)
BR (1) BR112015021027B1 (enExample)
CA (2) CA3007006A1 (enExample)
CL (1) CL2015002445A1 (enExample)
CR (2) CR20190504A (enExample)
CU (1) CU24340B1 (enExample)
CY (1) CY1121047T1 (enExample)
DK (1) DK2961742T3 (enExample)
EA (1) EA035127B1 (enExample)
ES (2) ES2688571T3 (enExample)
HK (2) HK1226078B (enExample)
HR (1) HRP20181679T1 (enExample)
HU (1) HUE039521T2 (enExample)
IL (1) IL240519B (enExample)
LT (1) LT2961742T (enExample)
MD (1) MD20150092A2 (enExample)
MX (1) MX375170B (enExample)
MY (1) MY195364A (enExample)
NZ (3) NZ631754A (enExample)
PE (2) PE20151749A1 (enExample)
PH (1) PH12015501881B1 (enExample)
PL (2) PL3409667T3 (enExample)
PT (2) PT2961742T (enExample)
RS (1) RS57718B1 (enExample)
SG (2) SG11201506929VA (enExample)
SI (2) SI2961742T1 (enExample)
SM (1) SMT201800522T1 (enExample)
TW (2) TWI694071B (enExample)
UA (1) UA120346C2 (enExample)
UY (1) UY35362A (enExample)
WO (1) WO2014134566A2 (enExample)
ZA (1) ZA201506098B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US9493429B2 (en) * 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
WO2016040084A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
RU2017138972A (ru) 2015-04-23 2019-05-23 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Ингибиторы репликации вируса иммунодефицита человека
JP2018513183A (ja) 2015-04-23 2018-05-24 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20170040479A1 (en) 2015-08-07 2017-02-09 Solaero Technologies Corp. Reliable interconnection of solar cells
US20170081324A1 (en) * 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2019519571A (ja) 2016-06-30 2019-07-11 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製のアザ置換阻害剤
US20190135857A1 (en) 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
US10493070B2 (en) 2016-06-30 2019-12-03 Viiv Healthcare Uk (No. 5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
EP3597646B1 (en) * 2016-08-19 2023-06-21 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
UY37710A (es) * 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US10696657B2 (en) * 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11505543B2 (en) 2018-04-11 2022-11-22 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
EP3833436A1 (en) * 2018-08-09 2021-06-16 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7398448B2 (ja) 2018-10-24 2023-12-14 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210393633A1 (en) * 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210403465A1 (en) 2018-10-29 2021-12-30 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3876942A1 (en) 2018-11-05 2021-09-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
EP3962603A1 (en) 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PE20220510A1 (es) 2019-06-19 2022-04-07 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2021064570A1 (en) 2019-10-01 2021-04-08 VIIV Healthcare UK (No.5) Limited N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
EP4041729B1 (en) 2019-10-08 2023-09-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
JPWO2021107066A1 (enExample) 2019-11-28 2021-06-03
MX2022006489A (es) * 2019-11-29 2022-07-04 Jiangsu Hengrui Medicine Co Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.
JP2023513047A (ja) * 2020-01-30 2023-03-30 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に有効な縮合二環式芳香族複素環式アミノ化合物
WO2021176367A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
CN115397424A (zh) 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
EP4361140A4 (en) * 2021-05-28 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co Ltd PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF FUSED CYCLIC PYRIDINE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250367382A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240393A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240387A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367385A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910133A (zh) * 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
WO2011019626A1 (en) * 2009-08-10 2011-02-17 Telcordia Technologies, Inc. System and method for the controlled introduction of noise to information filtering
CN101466676B (zh) * 2006-04-12 2012-07-18 默沙东公司 吡啶基酰胺类t-型钙通道拮抗剂
WO2013006738A1 (en) * 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
PE20120616A1 (es) 2009-02-25 2012-05-26 Bigtec Private Ltd Sondas y cebadores para la deteccion de chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
EP2588450B1 (en) 2010-07-02 2017-05-24 Gilead Sciences, Inc. Napht-2-ylacetic acid derivatives to treat aids
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
PL2688403T3 (pl) 2011-03-23 2017-09-29 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
CN102863512B (zh) * 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
CA2850881C (en) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
JP6466433B2 (ja) 2013-10-24 2019-02-06 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
WO2016040084A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP2018513183A (ja) 2015-04-23 2018-05-24 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
RU2017138972A (ru) 2015-04-23 2019-05-23 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Ингибиторы репликации вируса иммунодефицита человека
JP6620763B2 (ja) * 2017-01-16 2019-12-18 マツダ株式会社 電動車両

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466676B (zh) * 2006-04-12 2012-07-18 默沙东公司 吡啶基酰胺类t-型钙通道拮抗剂
CN101910133A (zh) * 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
WO2011019626A1 (en) * 2009-08-10 2011-02-17 Telcordia Technologies, Inc. System and method for the controlled introduction of noise to information filtering
WO2013006738A1 (en) * 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv

Also Published As

Publication number Publication date
JP2018141018A (ja) 2018-09-13
US9951043B2 (en) 2018-04-24
AU2016262671A1 (en) 2016-12-08
TWI694071B (zh) 2020-05-21
PE20191461A1 (es) 2019-10-16
PE20151749A1 (es) 2015-12-12
CN105705500B (zh) 2018-05-29
HUE039521T2 (hu) 2019-01-28
MX2015011478A (es) 2016-02-03
MD20150092A2 (ro) 2016-02-29
JP2023101723A (ja) 2023-07-21
IL240519A0 (en) 2015-10-29
CR20150454A (es) 2015-11-20
EP2961742B1 (en) 2018-08-01
EA201591457A8 (ru) 2018-05-31
AP2015008717A0 (en) 2015-09-30
TW201446755A (zh) 2014-12-16
JP2019214599A (ja) 2019-12-19
IL240519B (en) 2020-11-30
TW201938551A (zh) 2019-10-01
EA201591457A1 (ru) 2016-03-31
PH12015501881A1 (en) 2016-01-11
KR20150121720A (ko) 2015-10-29
CU20150096A7 (es) 2016-07-29
ES2688571T3 (es) 2018-11-05
JP2025085700A (ja) 2025-06-05
PT2961742T (pt) 2018-10-26
JP2022009742A (ja) 2022-01-14
MY195364A (en) 2023-01-16
CL2015002445A1 (es) 2016-02-19
PH12015501881B1 (en) 2016-01-11
ZA201506098B (en) 2022-05-25
US20160108030A1 (en) 2016-04-21
EP3954679A3 (en) 2022-04-20
PL2961742T3 (pl) 2018-12-31
SG10201710764YA (en) 2018-02-27
UA120346C2 (uk) 2019-11-25
RS57718B1 (sr) 2018-12-31
WO2014134566A2 (en) 2014-09-04
AU2016262671B2 (en) 2018-11-08
EP3954679A2 (en) 2022-02-16
CN105705500A (zh) 2016-06-22
EP3409667A1 (en) 2018-12-05
HK1222169A1 (en) 2017-06-23
DK2961742T3 (en) 2018-09-24
EP3409667B1 (en) 2021-07-21
MX375170B (es) 2025-03-06
HK1226078B (zh) 2017-09-22
PT3409667T (pt) 2021-09-16
AU2018247348A1 (en) 2018-11-08
AU2014223973A1 (en) 2015-09-10
BR112015021027A8 (pt) 2020-01-14
PL3409667T3 (pl) 2021-12-13
NZ742681A (en) 2019-05-31
CU24340B1 (es) 2018-05-08
UY35362A (es) 2014-08-29
NZ728537A (en) 2018-08-31
NZ631754A (en) 2017-02-24
BR112015021027A2 (pt) 2017-07-18
AU2014223973B2 (en) 2016-12-22
JP6519486B2 (ja) 2019-05-29
EA035127B1 (ru) 2020-04-30
JP6893899B2 (ja) 2021-06-23
CA2901502C (en) 2018-07-17
LT2961742T (lt) 2018-09-25
SMT201800522T1 (it) 2018-11-09
ES2887578T3 (es) 2021-12-23
WO2014134566A3 (en) 2014-12-24
CA3007006A1 (en) 2014-09-04
SG11201506929VA (en) 2015-10-29
CR20190504A (es) 2020-03-11
HK1260892A1 (zh) 2019-12-27
SI3409667T1 (sl) 2021-11-30
BR112015021027B1 (pt) 2020-02-18
US20180273508A1 (en) 2018-09-27
CY1121047T1 (el) 2019-12-11
TWI706945B (zh) 2020-10-11
KR102229989B1 (ko) 2021-03-18
SI2961742T1 (sl) 2018-11-30
CA2901502A1 (en) 2014-09-04
US20140303164A1 (en) 2014-10-09
EP2961742A2 (en) 2016-01-06
US20210009555A1 (en) 2021-01-14
HRP20181679T1 (hr) 2018-12-14
JP2016510038A (ja) 2016-04-04

Similar Documents

Publication Publication Date Title
CN105705500B (zh) 用于治疗hiv的酰胺化合物
HK1226078A1 (en) Amide compounds for the treatment of hiv
JP5925394B2 (ja) 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
HK40068501A (en) Amide compounds for the treatment of hiv infections
HK1222169B (en) Amide compounds for the treatment of hiv
HK40006176A (en) Amide compounds for the treatment of hiv infections
HK40006176B (en) Amide compounds for the treatment of hiv infections
OA17473A (en) Amide compounds for the treatment of HIV

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: G.Briggs

Inventor after: S*D*Schroeder

Inventor after: J.R.Sommerze

Inventor after: W*C*Tes

Inventor after: J*R*Zhang

Inventor after: S*E*Lazevis

Inventor after: R*L*Halcombe

Inventor after: E.Canares

Inventor after: Zhou Jianhong

Inventor after: M.Grapp

Inventor after: Y*E*Hu

Inventor after: J.O.Link

Inventor after: Liu Qi

Inventor after: Lu Yafan

Inventor after: R*D*Sattur

Inventor before: G.Briggs

Inventor before: S*D*Schroeder

Inventor before: J.R.Sommerze

Inventor before: W*C*Tes

Inventor before: J*R*Zhang

Inventor before: S*E*Lazevis

Inventor before: E.Canares

Inventor before: Zhou Jianhong

Inventor before: M.Grapp

Inventor before: Y*E*Hu

Inventor before: J.O.Link

Inventor before: Liu Qi

Inventor before: Lu Yafan

Inventor before: R*D*Sattur

CB03 Change of inventor or designer information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260892

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180911

WD01 Invention patent application deemed withdrawn after publication